Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
NCT07673900
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Overweight and/or Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Terrestrial Bio, Inc.
- Last updated on ClinicalTrials.gov
- July 31, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Celerion Clinical Research · Tempe, AZ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.